GPPAD

Furthermore, GPPAD provides researchers worldwide with the opportunity to conduct innovative research on biospecimens from the GPPAD studies, aiming to make significant advances in the study of the etiology, pathogenesis, and prevention of type 1 diabetes and other immune-mediated diseases... GPPAD conducts newborn screening in the general population to identify infants at high genetic risk of developing islet autoimmunity and type 1 diabetes. GPPAD investigators provide expert counseling to these families and invites them to participate in primary prevention studies. To date, over 500,000 infants have undergone screening, and more than 2,000 children are participating in the GPPAD prevention studies, POInT, SINT1A, and AVAnT1A. GPPAD also encompasses expert groups for celiac disease and allergy research... The Global Platform for the Prevention of autoimmune Diabetes (GPPAD) Research for world without TYPE 1 diabetes. A consortium of European research institutions

Primary location: Dresden United States